Search
Zaltoprofen
go.drugbank.com/drugs/DB06737InvestigationalA non-steroidal anti-inflammatory drug approved for use in Japan in 1993.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSCyclomethicone 5
go.drugbank.com/drugs/DB11244ApprovedCyclomethicone 5 is member of cyclomethicone, which are a group of liquid methyl siloxanes that have low viscosity and high volatility.
Zaleplon
go.drugbank.com/drugs/DB00962ApprovedIllicitZaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Synonyms: 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilideRipasudil
go.drugbank.com/drugs/DB13165InvestigationalRipasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered. … This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.
R1295
go.drugbank.com/drugs/DB05122ExperimentalIntegrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Cefovecin
go.drugbank.com/drugs/DB11505ExperimentalVet approvedIt is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. … The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses.
D-Asparagine
go.drugbank.com/drugs/DB03943ExperimentalA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase.
Technetium Tc-99m ciprofloxacin
go.drugbank.com/drugs/DB05488Experimental99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type